Advertisement

Topics

Shire receives FDA approval for Mydayis to treat attention deficit hyperactivity disorder

19:00 EDT 21 Jun 2017 | Pharmaceutical Technology

Biotechnology company Shire has received the US Food and Drug Administration (FDA) approval for Mydayis (mixed salts of a single-entity amphetamine product) for the treatment of attention deficit hyperactivity disorder (ADHD).

Original Article: Shire receives FDA approval for Mydayis to treat attention deficit hyperactivity disorder

NEXT ARTICLE

More From BioPortfolio on "Shire receives FDA approval for Mydayis to treat attention deficit hyperactivity disorder"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Biotechnology - Biotech
"using living things to create products or to do tasks for humans" About Biotechnology - Biotech Biotechnology is the practice of using plants, animals and micro-organisms such as bacteria, as well as biological processes - such as the ripen...

Drug Approvals
In order to become availible to pateints, drugs need to undergo a number of phases of clinical trials to test their efficacy and safty and to then be authorised by the drug approval organistion in each respective country. This is the FDA in the USA and N...